TGA-2023-0067-V267
Major variation for application TGA-2023-0067. Major variation: Formulation Change for Lecanemabix — critical change
Variation Number
TGA-2023-0067-V267
Type
Major
Application
Change
Status
Active
Fee
€35,006
Submitted
2023-07-03
Approved
—
Description
Major variation: Formulation Change for Lecanemabix — critical change